LSP says its new fund for medical device and drug development companies will be the biggest fund dedicated to life sciences companies in Europe.

Transcatheter aortic valve replacement pioneer Martin Leon discussed what is coming down the pike for technologies in the TAVR and heart valve device space at the recent Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego. Here is a run-down of what he highlighted, including AI-driven technologies that promise to improve patient access and outcomes. This is the first of a two-part series focusing on innovations in interventional cardiology. 

Hindsight 20/20 is a Q&A feature where medtech industry veterans share their experience taking diverse businesses – be they startups or publicly-listed entities – from strength to strength and navigating through times of crises. In this installment, Laurent Grandidier shares what he learned from his time at medtech multinationals, like Teleflex and Boston Scientific, and at startups like Endosense and, the firm he currently leads, Xeltis. He explains how a carefully planned, step-by-step approach is the best way to get investors to buy into a high-risk, high-reward investment proposition, and why sometimes you need to have the audacity to pivot and take a company in a different, more commercially viable direction.

Starts & Stops is a regular feature highlighting Medtech Insight editors' picks of noteworthy medtech clinical trial initiations, completions and suspensions each month. News about trials of cardiovascular devices, especially novel heart valve replacement technologies, lead this month's edition, covering mid-May through mid-June.